

Case report

Severe myelosuppression causing pancytopenia in a patient with Crohn's disease: an uncommon complication of azathioprineNimesha SNH¹, Jayasena H² ¹University Medical Unit, Colombo North Teaching Hospital, Ragama, Sri Lanka²Faculty of Medicine, General Sir John Kotelawala Defence University, Sri Lanka**Article Information****Corresponding Author**

H Jayasena

Email: hiru65@hotmail.com

 <https://orcid.org/0000-0001-5175-0803>

Received 03 June 2024

Revised version 13 June 2024

Accepted 24 July 2024

Conflicts of Interest: None**Abstract**

Azathioprine, is widely used to treat many diseases as a steroid sparing drug, including inflammatory bowel disease. Whilst it can commonly result in leucopenia, in rare instances, it can cause severe myelosuppression and pancytopenia. We present a patient with Crohn's disease, who developed severe myelosuppression resulting in pancytopenia and neutropenic sepsis secondary to azathioprine use.

Keywords: azathioprine, Crohn's disease, diarrhoea, pancytopenia**Introduction**

Azathioprine, a purine analogue, is widely used to treat many diseases as a steroid sparing drug, including inflammatory bowel disease (IBD). It is well absorbed by the gastrointestinal tract and has a serum half-life of 0.2-0.5 hours with biological half-life of 24 hours.¹ Azathioprine exerts its action by inhibiting purine and protein synthesis in lymphocytes.² Azathioprine is a prodrug that is converted to 6-mercaptopurine via non-enzymatic nucleophilic attack by sulphhydryl contain products like glutathione in red cells and other tissues. In addition, it also inhibits the proliferation of T lymphocytes, B lymphocytes as well as plasma cells and causes apoptosis of T cells.² Whilst it can commonly result in leucopenia, in rare instances, it can cause severe myelosuppression and pancytopenia.

Usually, the dosing of azathioprine is either based on gradual adjustment of the dose or on TPMT gene studies. TPMT activity influences the incidence of adverse effects particularly bone marrow toxicity.³ The most widely used method is that of by gradual adjustment of dose as genetic studies are widely unavailable and can be costly. Consequently, patients are started on a small dose of azathioprine and the dose is gradually raised to the therapeutic desired range, whilst clinicians monitor for potential complications. There are "dose

Cite this article as: Jayasena H, et al. Severe myelosuppression causing pancytopenia in a patient with Crohn's disease: an uncommon complication of azathioprine. SLJMS 2024; 1(1): 43-45.



This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution and reproduction in any medium provided the original author and source are credited.

independent” and “dose dependant” side effects of azathioprine. Most common dose independent side effects include gastrointestinal side effects such as anorexia, nausea, vomiting and pancreatitis.⁴ The dose dependant side effects on the other hand include infections, bone marrow suppression hepatotoxicity and alopecia.⁵ Dose related bone marrow suppression results in neutropenia in approximately 17%, whilst thrombocytopenia occurs in up to 5%.^{1,4} Nevertheless severe pancytopenia with azathioprine affecting all three cell lines is not common, with a reported incidence of 0.4-2% of cases in IBD treated with azathioprine.⁶

Case report

A 15-year-old Sinhalese boy, who had previously been diagnosed three months prior with Crohn’s disease, presented to tertiary centre in Western province, with persistent fever for seven days. Following his initial diagnosis of Crohn’s disease, he was commenced on reducing course of prednisolone as well as azathioprine 25 mg daily, which was later increased gradually to 75 mg over a two-month period. The patient was symptomatically improved with weight gain and appetite noted. Despite improvement in bowel symptoms, he noted that there was increased loss of hair. Two weeks after commencement of increased dose of azathioprine 75mg per day, he presented with severe sore throat, myalgia and fever lasting for one day. There had been no concurrent medications (ayurvedic or herbal) used by the patient.

On examination he was febrile, flushed and the oropharynx appeared inflamed with no pustular formation. The full blood count (FBC) on admission showed severe pancytopenia with white blood cells (WBC) of 1.3×10^3 , absolute neutrophil count of 0.16×10^3 , Haemoglobin (Hb) of 10g/dl with a platelet count of 5×10^3 . Given the high prevalence of Dengue fever in Sri Lanka, the initial suspicion was that of Dengue fever. However, NS 1 antigen done on the day two of fever was negative, along with a negative dengue IgM and IgG. The blood picture demonstrated evidence of pancytopenia with normochromic normocytic anaemia, leukopenia and markedly reduced platelets with evidence of possible bacterial infection. There were no atypical cells noted. The C- reactive protein (CRP) level was 233 with an Erythrocyte sedimentation rate (ESR) of 40 mm on admission. Cultures including blood, urine and throat swab were repeatedly negative. The reticulocyte count was 0.13% with a reticulocyte index of 0.05 showing evidence of bone marrow hypo-proliferation. Hence, he was managed as neutropenic sepsis and azathioprine was withheld on suspicion of possible toxicity.

In treating neutropenic sepsis, the patient was commenced on intravenous piperacillin-tazobactam, after taking

cultures. Along with it, he was commenced on twice daily doses of granular colony stimulating factor (GCSF), following a bone marrow biopsy to identify the cause of severe pancytopenia. The patient responded well to treatment and was afebrile by day three of treatment.

The WBC counts improved with GCSF and by day four, the WBC raised to 4.30×10^6 /mL with absolute neutrophil count of 1.14×10^6 /mL. However, his platelet count remained slow to respond with a count of only 4×10^6 /mL. The other investigations including liver function test, lactate dehydrogenase level and serum creatinine remained normal. The bone marrow demonstrated presence of severe bone marrow suppression with possibility of drug induced bone marrow suppression. Parvo virus antibodies were found to be negative. The chest x ray was completely normal as well as sputum cultures which were negative for acid fast bacilli. Furthermore, GeneXpert studies for tuberculosis and bone marrow tuberculosis polymerase chain reaction test both yielded negative results.

With stopping of the drug and timely treatment of the concomitant neutropenic sepsis, the patient gradually improved. By day ten, patient was asymptomatic with WBC of 10.84×10^6 /mL, an absolute neutrophil count of 6.33×10^6 /mL, and platelets were 30×10^6 /mL. Azathioprine was completely withheld, and patient was switched to biological therapy of infliximab for Crohn’s disease. Prior to commencing on infliximab, screening for HIV, viral hepatitis including cytomegalovirus (CMV) and Epstein Barr virus (EBV) was completed. He remained asymptomatic during the follow up and FBC parameters were persistently within normal range.

Discussion

Azathioprine is one of the most used drugs to maintain remission in IBD. As the main action of azathioprine is on the lymphocytes, the most common feature of bone marrow suppression is to present as leucopenia. However, in rare instances it can cause severe life-threatening pancytopenia, as it did in our patient. Studies have shown that 1 in 4 patients, who were treated with azathioprine, have developed drug related complications.⁷ It is common mostly during the first month of starting azathioprine.⁷ Approximately in 20% of the cases, the side effects were severe enough to warrant cessation of treatment.⁷ Owing to its side effects, the use of TPMT levels in optimizing and guiding azathioprine treatment in IBD is practised in developed countries.⁸ Myelosuppression has been associated with low Thiopurine methyltransferase (TPMT) levels.⁹ Unfortunately, due to the high cost of TPMT gene analysis and unavailability, TPMT levels were not sent in this patient prior to starting azathioprine, which could have helped to predict response to treatment. The

above-mentioned patient presented with fever and features of sepsis. It is worth noting that it is common for pancytopenia to present as an underlying infection and neutropenic sepsis. The raised ESR and CRP both suggested the presence of an infection. However, all the peripheral cultures including blood, urine, throat swabs and bone marrow negative for any bacterial or tuberculosis infections. Parvo virus B19 antibodies negative and was done to exclude possible common cause for pancytopenia in young. Furthermore, prior to biological therapy commencement, the patient had screening for HIV, viral hepatitis including cytomegalovirus (CMV) and Epstein Barr virus (EBV) all of which can cause pancytopenia, which were all negative. Bone marrow trephine biopsy showed evidence of severe pancytopenia, without evidence of malignancy and with the possibility of drug induction as suggested by the history. The severe alopecia was also accounted for by azathioprine toxicity, in this patient, given the severe hair loss and pancytopenia, azathioprine was omitted altogether. Following the cessation of azathioprine, both clinical and biochemical parameters returned to normal. Given the short course of illness, with diagnosis only occurring 3 months prior with good nutritional status, it was unlikely that the patient had significant nutritional deficiencies related to Crohn's disease to cause pancytopenia. Inability to check iron studies, vitamin B₁₂ and folate levels was a limitation in this study.

Conclusion

Even though the common side effects of azathioprine are not dangerous, there remains few life-threatening side effects such as severe liver injury and severe pancytopenia. Hence vigilant monitoring is required when commencing or on dose adjustment of azathioprine is done. TPMT levels would help to identify those at risk of developing severe side effects due to azathioprine. If proper follow up, necessary investigations and timely interventions are not done, these patients can easily be missed.

Author Contribution

All authors equally contributed to the study.

References

1. Huskisson EC. Azathioprine. *Clinics in rheumatic diseases*. 1984; **10**(2): 325-32.
2. Rios-Usuga C, Martinez-Gutierrez M, Ruiz-Saenz J. Antiviral Potential of Azathioprine and Its Derivative 6-Mercaptopurine: A Narrative Literature Review. *Pharmaceuticals* (Basel). 2024; **17**(2): 174.
3. Dong XW, Zheng Q, Zhu MM, et al. Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease. *World J Gastroenterol* 2010; **16**: 3187-95.
4. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. *American Journal of Human Genetics* 1980; **32**(5): 651.
5. Broekman MMTJ, Coenen MJH, van Marrewijk CJ, et al. More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing. *Inflamm Bowel Dis*. 2017; **23**(10): 1873-81.
6. Telm A, Schaeffeler E, Herlinger KR, et al. Thiopurine treatment in inflammatory bowel disease. *Clin Pharmacokinet* 2007; **46**: 187-208.
7. Chaparro M, Ordás I, Cabré E, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. *Inflammatory bowel diseases*. 2013; **19**(7): 1404-10.
8. Warner B, Johnston E, Arenas-Hernandez M, et al. *Frontline Gastroenterology* 2018; **9**: 10-15.
9. Hindorf U, Lindqvist M, Hildebrand H, et al. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. *Aliment Pharmacol Ther*. 2006; **24**: 331-42.